NCT01877187 - Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions

Liver Cancer

Interventions

DRUG

Lipiodol

Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).

Trial Locations (2)

21287

The Johns Hopkins Hospital, Baltimore

06510

Smilow Cancer Center, New Haven